Table 1 Distribution of patients within each treatment arm by simplified MIPI risk category [13,14]
Patients | Low risk | Intermediate risk | High risk |
|---|---|---|---|
n (%) | n (%) | n (%) | |
All patients (N = 162) | 51 (31) | 63 (39) | 48 (30) |
Temsirolimus 175/75 mg (n = 54) | 14 (26) | 24 (44) | 16 (30) |
Temsirolimus 175/25 mg (n = 54) | 15 (28) | 18 (33) | 21 (39) |
INV therapy (n = 54) | 22 (41) | 21 (39) | 11 (20) |